Endoglin (CD105) as a urinary and serum marker of prostate cancer

International Journal of Cancer

Volumn 124, Issue 3, 2009, Pages 664-669

  Fujita, Kazutoshi ^a   Ewing, Charles M ^a   Chan, David Y S ^a   Mangold, Leslie A ^a   Partin, Alan W ^a   Isaacs, William B ^a   Pavlovich, Christian P ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biological markers; CD105; Clinical markers; Endoglin; Prostate cancer

Indexed keywords

ENDOGLIN; PROSTATE SPECIFIC ANTIGEN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; URINALYSIS; AREA UNDER THE CURVE; BLOOD; MIDDLE AGED; PROSTATE TUMOR; ROC CURVE; URINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; AREA UNDER CURVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 58149290234     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24007     Document Type: Article

References (20)

1. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
2. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9.
3. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, Kader AK, Turner AR, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-19.
4. Wright JL, Lange PH. Newer potential biomarkers in prostate cancer. Rev Urol 2007;9:207-13.
5. Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, Cunningham M, De Marzo AM, Isaacs WB, Pavlovich CP. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 2008;68:872-82. Supplementary Table available at: http://www.interscience.wiley.com/ jpages/0270-4137/suppmat/index.html.
6. Bernabeu C, Conley BA, Vary CP. Novel biochemical pathways of endoglin in vascularcell physiology. J Cell Biochem 2007;102:1375-88.
7. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, Saad RS. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007;127:572-9.
8. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001;7:524-32.
9. Kassouf W, Ismail HR, Aprikian AG, Chevalier S. Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer. Prostate Cancer Prostatic Dis 2004;7:105-10.
10. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res 2008;14:1418-22.
11. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 2008;14:3362-6.
12. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
13. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE, Jr, Zeitlin S, O'Leary MP, Pontari MA, Schaeffer AJ, Landis JR, Nyberg L, Kusek JW, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006;176:119-24.
14. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ. Early detection of prostate cancer in 2007 Part 1: PSA and PSA kinetics. Eur Urol 2008;53:468-77.
15. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
16. Cruz-Gonzalez I, Pabon P, Rodriguez-Barbero A, Martin-Moreiras J, Pericacho M, Sanchez PL, Ramirez V, Sanchez-Ledesma M, Martin-Herrero F, Jimenez-Candil J, Maree AO, Sanchez-Rodriguez A, et al. Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med 2008;12:955-61.
17. Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, Maly J, Smolej L, Zajic J, Masin V, Zimova R, Rehacek V. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis 2008;197:264-70.
18. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17:984-92.
19. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43799-808.
20. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 2000;14:55-64.